Acute Myeloid Leukemia
6 competing products in clinical development for Acute Myeloid Leukemia.
Pipeline by Phase
Phase 16
All Products (6)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| PRGN-3006 T Cells | Precigen | Phase 1 | Active | 28 |
| AFM28 | Affimed | Phase 1 | Terminated | 25 |
| Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridine | Race Oncology | Phase 1 | Withdrawn | 25 |
| ZN-d5 | Zentalis Pharmaceuticals | Phase 1 | Completed | 25 |
| VIP943 (QW) + VIP943 (BIW) | Vincerx Pharma | Phase 1 | Recruiting | 25 |
| Tomivosertib | eFFECTOR Therapeutics | Phase 1 | Active | 25 |